十二指肠间质瘤的临床病理学特点和外科治疗进展

发布时间：2018-05-02 07:25

本文选题：十二指肠间质瘤 + 伊马替尼　；参考：《中国肿瘤临床》2017年04期

【摘要】：十二指肠胃肠道间质瘤(gastrointestinal stromal tumors,GISTs)是起源于消化道卡哈尔间质细胞(interstitial cells of Cajal,ICCs)一种少见的亚群。虽然影像学、内镜技术和病理免疫组织化学已经取得显著的进步,但术前仍很难达到完全确诊。内镜超声下细针穿刺活检被认为是诊断的金标准,具有很高的敏感性和特异性,GISTs诊断率高达80%。对于非转移性原发的十二指肠GISTs,获得显微镜下阴性切缘的手术切除仍是潜在治愈性治疗手段,但由于胰十二指肠区域的复杂解剖,最佳治疗策略仍具有挑战性。复发风险和无瘤生存时间取决于肿瘤大小、核分裂数和美国国立卫生研究院(national institutes of health,NIH)复发风险分层,而不是手术方式。伊马替尼作为新辅助治疗,对治疗复发和转移性GISTs起到重要作用。对十二指肠GISTs的病理生理和治疗方式的全面深入研究将有利于发现更新且更有效的治疗方式。
[Abstract]:Gastrointestinal stromal tumors (GISTs) is a rare subgroup originating from the interstitial cells of Cajal (ICCs) in the digestive tract (interstitial cells of Cajal, ICCs). Although imaging, endoscopic technique and pathological immuno histochemistry have made remarkable progress, it is still difficult to achieve complete diagnosis before surgery. Fine needle aspiration biopsy is considered as a diagnostic gold standard with high sensitivity and specificity. The diagnostic rate of GISTs is up to 80%. for non metastatic primary duodenal GISTs. The surgical removal of the negative margin under the microscope is still a potential cure, but the best treatment strategy is due to the complex anatomy of the pancreas and duodenum. The recurrence risk and tumor free survival time depend on the size of the tumor, the number of nuclear mitosis and the recurrence risk of the National Institutes of Health (National Institutes of health, NIH), rather than the mode of operation. Imatinib plays an important role in the treatment of relapse and metastatic GISTs as a neoadjuvant therapy. For duodenal GIST A comprehensive and in-depth study of pathophysiology and treatment modalities of s will help to identify newer and more effective treatments.

【作者单位】：天津医科大学肿瘤医院肝胆肿瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心;
【分类号】：R735.31

【参考文献】